Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2 … R Mistry, JR May, G Suri, K Young, D Brixner, G Oderda, J Biskupiak, ... Journal of managed care & specialty pharmacy 24 (6), 514-523, 2018 | 78 | 2018 |
Vaccine wastage at the level of service delivery: a cross-sectional study C Duttagupta, D Bhattacharyya, P Narayanan, SM Pattanshetty Public Health 148, 63-65, 2017 | 17 | 2017 |
Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report MF Drummond, F Augustovski, D Bhattacharyya, J Campbell, ... Value in Health 25 (8), 1257-1267, 2022 | 13 | 2022 |
Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective T Purmonen, K Puolakka, D Bhattacharyya, M Jain, J Martikainen Cost Effectiveness and Resource Allocation 16, 1-10, 2018 | 12 | 2018 |
A cross-sectional study to identify the factors associated with utilisation of healthcare for non-communicable diseases in a southern part of India D Bhattacharyya, SM Pattanshetty, C Duttagupta Int J Med Sci Public Health 6 (1), 96-101, 2017 | 9 | 2017 |
Necrotic enteritis in poultry in West Bengal. GC Chakraborty, D Chakraborty, D Bhattacharyya, S Bhattacharyya, ... | 9 | 1984 |
Cost-effectiveness of secukinumab versus other biologics in the treatment of psoriatic arthritis: an Argentinean perspective E Aiello, PM Bianculli, D Bhattacharyya, P Gunda, G Citera Value in Health Regional Issues 20, 86-94, 2019 | 8 | 2019 |
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2− advanced or metastatic … R Mistry, G Suri, K Young, R Hettle, JR May, D Brixner, G Oderda, ... Current Medical Research And Opinion 34 (12), 2143-2150, 2018 | 7 | 2018 |
Broiler chick mortality due to pullorum disease and brooder pneumonia in West Bengal. HM Bhattacharyya, GC Chakraborty, D Chakraborty, D Bhattacharyya, ... | 7 | 1984 |
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation. R Bresnahan, R Duarte, J Mahon, S Beale, M Chaplin, D Bhattacharyya, ... Health Technology Assessment (Winchester, England) 27 (10), 1, 2023 | 2 | 2023 |
Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic … WG Gathirua-Mwangi, H Sethi, MG Afable, D Bhattacharyya, T Khan Journal of Medical Economics 24 (1), 1164-1172, 2021 | 2 | 2021 |
Cost effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole for the treatment of post-menopausal women with hormone receptor-positive (HR+), human … G Suri, R Mistry, KC Young, R Hettle, JR May, D Brixner, G Oderda, ... Value in Health 20 (9), A436, 2017 | 2 | 2017 |
Scoping review of non-pharmacological interventions to control H1N1 in India J Sharma, D Bhattacharyya, K Poddar, TC Pavithran, H Thakur Clinical Epidemiology and Global Health 7 (3), 504-508, 2019 | 1 | 2019 |
Budget impact of ribociclib plus letrozole for the treatment of post-menopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative … R Mistry, G Suri, KC Young, R Hettle, JR May, D Brixner, G Oderda, ... Value in Health 20 (9), A422-A423, 2017 | 1 | 2017 |
Assessment of clinical effectiveness: direct evidence N Fleeman, R Houten, S Nevitt, J Mahon, S Beale, A Boland, ... Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a …, 2024 | | 2024 |
Assessment group network meta-analyses N Fleeman, R Houten, S Nevitt, J Mahon, S Beale, A Boland, ... Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a …, 2024 | | 2024 |
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. N Fleeman, R Houten, S Nevitt, J Mahon, S Beale, A Boland, ... Health technology assessment (Winchester, England) 28 (49), 1, 2024 | | 2024 |
POSTER: CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third-or Later-Line Chronic Myeloid Leukemia in … E Atallah, K Jadhav, T Kangappaden, A Damon, I Samjoo, D Wei, ... Clinical Lymphoma Myeloma and Leukemia 23, S176, 2023 | | 2023 |
CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third-or Later-Line Chronic Myeloid Leukemia in Chronic Phase … E Atallah, K Jadhav, T Kangappaden, A Damon, I Samjoo, D Wei, ... Clinical Lymphoma Myeloma and Leukemia 23, S337-S338, 2023 | | 2023 |
P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA E Atallah, A Yocolly, K Jadhav, T Kangappaden, A Damon, IA Samjoo, ... HemaSphere 7 (Suppl), 2023 | | 2023 |